BioCentury
ARTICLE | Company News

Valeant prices Siliq

April 21, 2017 10:05 PM UTC

Valeant Pharmaceuticals International Inc. (TSX:VRX; NYSE:VRX) priced psoriasis treatment Siliq brodalumab at a wholesale acquisition cost (WAC) of $3,500 per month, which it said is the lowest for a marketed injectable biologic psoriasis treatment.

Competitor Humira adalimumab from AbbVie Inc. (NYSE:ABBV) has a monthly WAC of about $4,800. Cosentyx secukinumab from Novartis AG (NYSE:NVS; SIX:NOVN) and Enbrel etanercept from Amgen Inc. (NASDAQ:AMGN) have monthly WACs of $4,308 and $4,422, respectively, according to the Red Book...